Humana Coverage Policy For Gilenya Promotes Second-Line Use
Executive Summary
Humana’s medical coverage policy for Novartis’ new multiple sclerosis drug Gilenya (fingolimod) requires prior authorization documenting the patient has already tried and failed treatment with other drugs.
You may also be interested in...
Gilenya Could Surpass Avonex Market Share, Analysts Say
Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.
Gilenya Could Surpass Avonex Market Share, Analysts Say
Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.
Novartis' Gilenya: Efficacy, Patient Assistance Lie At Heart Of Marketing Push
As Novartis' multiple sclerosis treatment Gilenya (fingolimod) hits the market, the company is hoping to move beyond the fact that the drug is the first-ever oral drug for general treatment for the disease and highlight its clinical efficacy compared with other MS drugs.